Post kala-azar dermal leishmaniasis (PKDL) may not be fatal, but it can be severely disfiguring with rashes that affect the face. To contribute to the end of kala-azar in India, there is a need to better understand all aspects of PKDL. And critically, there is a need to provide more adapted tools to treat people living with the disease.
DNDi aims to develop shorter and safer treatments with high efficacy that could be used on an out-patient basis. Vishal Goyal, Senior Clinical Manager at DNDi, explains more about a clinical study that has started in India and is about to start in Bangladesh and in Sudan to assess new treatments for PKDL.